Should 3-weekly docetaxel (3WD) remain the standard for second-line therapy of advanced non-small-cell lung cancer (A-NSCLC)? Meta-analysis of 7 randomized clinical trials (RCTs) with 3WD comparator ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results